Nicox

[Not Yet Scheduled]
Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health.

We are maximizing value by advancing our product candidates through clinical development to approval in the U.S. and EU markets, optimizing their development and commercialization in the rest of the world through partnerships, and potentially expanding our pipeline with new internal research and development projects, in-licensing or acquisitions of ophthalmic development candidates or approved products.

Our ophthalmic pipeline includes two programs in clinical development, NCX 470 targeting glaucoma and NCX 4251 targeting dry eye disease. We also have two products which are commercialized in the U.S., VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis, respectively.
Ticker:
COX
Exchange:
Euronext Paris
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
France
Year Founded:
1996
Main Therapeutic Focus:
Lead Product in Development:
NCX 470
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Vice President Business Develepment
NicOx, SA